Valuing a closely held business is often a debate over hypothetical dollars, particularly when the company’s sole asset is unproven technology. The Business Court confronted such a situation recently in Vernon v. Cuomo.
The company in question developed a new technology with potential widespread medical application: silicone-free syringes, which would enable syringes (especially of high-priced
